Safety and Tolerability of High-Intensity Anticoagulation with Bivalirudin During Neuroendovascular Procedures
- 19 August 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurocritical Care
- Vol. 15 (1), 96-100
- https://doi.org/10.1007/s12028-010-9421-7
Abstract
Bivalirudin (Angiomax) is a direct thrombin inhibitor used in interventional cardiology due to its several distinct advantages over heparin, most notably a shorter half-life and a potentially superior safety profile. Bivalirudin is also safe to use in patients with active or remote heparin-induced thrombocytopenia. Our objective was to evaluate the safety and tolerability of high-intensity anticoagulation using bivalirudin during neuroendovascular procedures.Keywords
This publication has 22 references indexed in Scilit:
- Carotid stenting and bivalirudin with and without vascular closure: 3‐year analysis of procedural outcomesCatheterization and Cardiovascular Interventions, 2010
- Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trialThe Lancet, 2009
- Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudinVascular Health and Risk Management, 2008
- Adjunct bivalirudin dosing protocol for neuro-endovascular procedures.2008
- Evaluating the Optimal Activated Clotting Time During Carotid Artery StentingThe American Journal of Cardiology, 2006
- Routine Bivalirudin Use in Percutaneous Carotid InterventionsJournal of Endovascular Therapy, 2005
- Direct thrombin inhibitors (part 1 of 2).2005
- Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trialJournal of the American College of Cardiology, 2004
- Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)The American Journal of Cardiology, 2004
- Prevention and Treatment of Thromboembolic and Ischemic Complications Associated with Endovascular Procedures: Part II???Clinical Aspects and RecommendationsNeurosurgery, 2000